Phase I and Clinical Pharmacology Trial of Crisnatol (BWA770U Mesylate) Using a Monthly Single-Dose Schedule

Glenn S. Harman, John B. Craig, John G. Kuhn, J. Scott Luther, Judy N. Turner, Geoffrey R. Weiss, Dennis A. Tweedy, Jim Koeller, Richard L. Tuttle, V. Sol Lucas, William Wargin, John K. Whisnant, Daniel D. Von Hoff

    Research output: Contribution to journalArticlepeer-review

    20 Scopus citations


    Crisnatol is a novel lipophilic arylmethylaminopropanediol with significant antineoplastic activity in a variety of murine and human tumor models which functions as a DNA intercalator. In this Phase I trial, a 6-h infusion of the drug was administered i.v. in 700 to 1500 ml of 5% dextrose in water every 28 days. Eighty-five courses at doses of 7.5 to 516 mg/m2 were administered to 43 patients with refractory solid tumors. Reversible neurological toxicity was dose limiting at 516 mg/m2 and was manifested as somnolence, dizziness, blurred vision, unsteady gait, and α-slowing on electroencephalogram at the end of infusion. All neurological signs and symptoms were reversible. No hematological toxicity was observed. Other toxicities included phlebitis, mild to moderate nausea and vomiting, reversible sinus node arrest in one patient, and hypertension. Crisnatol plasma concentrations were determined by high-pressure liquid chromatography. After infusion, plasma concentrations declined biexponentially with a terminal tv, of 2.9 h. Using a two-compartment model, the mean apparent volume of distribution at steady state and total-body clearance were 58.8 liters/m2 and 183 liters/h/m2, respectively, indicative of extensive tissue distribution and rapid hepatic clearance. Peak plasma levels occurred at the end of infusion and correlated with the onset of neurological toxicity. The recommended Phase II dose for this schedule is 388 mg/m2.

    Original languageEnglish (US)
    Pages (from-to)4706-4710
    Number of pages5
    JournalCancer Research
    Issue number16
    StatePublished - 1988

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research


    Dive into the research topics of 'Phase I and Clinical Pharmacology Trial of Crisnatol (BWA770U Mesylate) Using a Monthly Single-Dose Schedule'. Together they form a unique fingerprint.

    Cite this